

Genomic surveillance of SARS-CoV-2 positive passengers on flights from China to Italy, December 2022

Federica Novazzi^{1,2,*}, Emanuela Giombini^{3,*}, Martina Rueca³, Andreina Baj^{1,2}, Lavinia Fabeni³, Angelo Genoni^{1,2}, Francesca Drago Ferrante², Giulia Gramigna³, Cesare Ernesto Maria Gruber³, Sara Boutahar², Claudia Minosse³, Ornella Butera³, Renee Pasciuta¹, Daniele Focosi⁴, Alberto Colombo¹, Andrea Antinori³, Enrico Girardi³, Francesco Vaia³, Fabrizio Maggi³

1. Laboratory of Microbiology, ASST SetteLaghi, Varese, Italy
2. Department of Medicine and Surgery, University of Insubria, Varese, Italy
3. National Institute for Infectious Diseases "L. Spallanzani" - IRCCS, Rome, Italy
4. North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy

* These authors contributed equally to this work and share first authorship.

Correspondence: Fabrizio Maggi (fabrizio.maggi@inmi.it)

Citation style for this article:

Novazzi Federica, Giombini Emanuela, Rueca Martina, Baj Andreina, Fabeni Lavinia, Genoni Angelo, Ferrante Francesca Drago, Gramigna Giulia, Gruber Cesare Ernesto Maria, Boutahar Sara, Minosse Claudia, Butera Ornella, Pasciuta Renee, Focosi Daniele, Colombo Alberto, Antinori Andrea, Girardi Enrico, Vaia Francesco, Maggi Fabrizio. Genomic surveillance of SARS-CoV-2 positive passengers on flights from China to Italy, December 2022. *Euro Surveill.* 2023;28(2):pii=2300008. <https://doi.org/10.2807/1560-7917.ES.2023.28.2.2300008>

Article submitted on 05 Jan 2023 / accepted on 12 Jan 2023 / published on 12 Jan 2023

With numbers of COVID-19 cases having substantially increased at the end of 2022 in China, some countries have started or expanded testing and genomic surveillance of travellers. We report screening results in Italy in late December 2022 of 556 flight passengers in provenance from two Chinese provinces. Among these passengers, 126 (22.7%) tested SARS-CoV-2 positive. Whole genome sequencing of 61 passengers' positive samples revealed Omicron variants, notably sub-lineages BA.5.2.48, BF.7.14 and BQ.1.1, in line with data released from China.

Following relaxation since September 2022, of measures related to 'zero-COVID' policies, a substantial increase in coronavirus disease (COVID-19) cases has been observed in China [1,2]. In a preprint article, the cumulative infection attack rate (i.e. the proportion of population who has been infected since 1 November) in Beijing was reported to be 43.1% (95% credible interval (CrI): 25.6–60.9) on 14 December and 75.7% (95% CrI: 60.7–84.4) on 22 December 2022 [3]. In reaction to this situation, a number of countries have recently required passengers on planes from mainland China to have a negative SARS-CoV-2 test, taken shortly pre-departure [4,5]. Moreover, some countries are testing incoming passengers from China for SARS-CoV-2 at arrival and/or are conducting/expanding genomic surveillance of travellers to monitor SARS-CoV-2 variants [4–6].

Here we report the results of screening that was conducted in Italy between 26 December and 29 December 2022 on flight passengers from China arriving at two major airports, namely Fiumicino Leonardo da Vinci airport in Rome and Malpensa airport in Milan.

Screening passengers for SARS-CoV-2 and variants identified

A total of 556 passengers from four flights were screened for SARS-CoV-2. Of these, 126 (22.7%) tested positive. The proportion of passengers detected with SARS-CoV-2 per flight ranged from 11 to 42% (Table). For 61 passengers (10.9% of the total 556; mean age: 49 years; 60% male; 40% females), who tested SARS-CoV-2 positive with a PCR quantification cycle (Cq) ≤ 25.0 , respective samples were subjected to whole genome sequencing by using next-generation sequencing (NGS) technology in two reference laboratories. The mean Cq derived from samples of these 61 passengers was 22.9 (range: 11.1–25.0).

The Table shows that three Omicron (Phylogenetic Assignment of Named Global Outbreak (Pango) lineage: B.1.1.529) sub-lineages are dominant: BA.5.2.48 (i.e. BA.5.2+T17208C) (n=30, 49%), BF.7.14 (i.e. BF.7+ORF7a:H47Y+S:C1243F) (n=18, 29%), and BQ.1.1+ORF1a:E754K (n=7, 11%). None of these sub-lineages detected from China have spike receptor-binding domain (RBD) mutations compared with their parental lineages, and therefore likely do not pose any threat in terms of immune evasion. None of the mutations detected have been clearly associated with any changes in transmissibility or disease severity.

Variant sub-lineage distributions according to passengers' departure town and comparison with data from China

The flights arriving to Italy from which passengers were screened originated from three cities in East China (Figure 1) including one (Nanjing) in Jiangsu province and two (Hangzhou and Wenzhou) in Zhejiang province.

TABLE

Number of passengers screened and testing positive for SARS-CoV-2 among incoming flights from China, as well as characteristics of sequenced viral strains (n = 61), stratified by city of departure and arrival airport in Italy, 26–29 December 2022 (n = 556 passengers screened)


Arrival airport (town) in Italy	Date in 2022	Flight provenance: city (province) of China	Total number of passengers	Number of passengers testing SARS-CoV-2-positive ^a	Percentage of passengers testing SARS-CoV-2 positive	Number of passengers for whom a viral sequence was obtained	Number of passengers according to: virus sub-lineage	GISAID entries
Malpensa airport (Milan)	26 Dec	Nanjing (Jiangsu)	177	33	19	13	3: BA.5.2.48 4: BF.7.14 3: BQ.1.1+ORF1a:E754K 3 NA	EPI_ISL_16343199; EPI_ISL_16343202; EPI_ISL_16343206; EPI_ISL_16343207; EPI_ISL_16343200; EPI_ISL_16343201; EPI_ISL_16343209; EPI_ISL_16343203; EPI_ISL_16343205; EPI_ISL_16343208
	26 Dec	Wenzhou (Zhejiang)	149	62	42	18	9: BA.5.2.48 5: BF.7.14 2: BQ.1.1+ORF1a:E754K 2: NA	EPI_ISL_16350707; EPI_ISL_16350809; EPI_ISL_16350829; EPI_ISL_16352121; EPI_ISL_16352120; EPI_ISL_16350963; EPI_ISL_16350831; EPI_ISL_16352309; EPI_ISL_16352019; EPI_ISL_16350964; EPI_ISL_16352119; EPI_ISL_16352115; EPI_ISL_16352093; EPI_ISL_16352118; EPI_ISL_16352122; EPI_ISL_16352117
Fiumicino Leonardo da Vinci airport (Rome)	29 Dec	Hangzhou (Zhejiang)	46	5	11	5	3: BA.5.2.48 2: BF.7.14	EPI_ISL_16355498; EPI_ISL_16355496; EPI_ISL_16355500; EPI_ISL_16354105; EPI_ISL_16354104
	29 Dec	Wenzhou (Zhejiang)	184	26	14	25	15: BA.5.2.48 7: BF.7.14 2: BQ.1.1+ORF1a:E754K 1: NA	EPI_ISL_16355502; EPI_ISL_16355499; EPI_ISL_16355503; EPI_ISL_16355501; EPI_ISL_16355504; EPI_ISL_16354103; EPI_ISL_16355505; EPI_ISL_16354102; EPI_ISL_16355487; EPI_ISL_16355484; EPI_ISL_16354101; EPI_ISL_16355486; EPI_ISL_16355489; EPI_ISL_16355488; EPI_ISL_16355485; EPI_ISL_16355495; EPI_ISL_16354100; EPI_ISL_16354099; EPI_ISL_16355492; EPI_ISL_16355491; EPI_ISL_16355494; EPI_ISL_16355493; EPI_ISL_16355490; EPI_ISL_16355497

NA: not assigned due to low sequence coverage; SARS-CoV-2: severe acute respiratory coronavirus 2.

^a According to the local regulations, SARS-CoV-2 infection was evaluated by real-time PCR and antigen detection in Malpensa airport (Milan) and Fiumicino Leonardo da Vinci airport (Rome), respectively. Antigen positive samples were then confirmed by real-time PCR.

FIGURE 1

Geographic distribution of Omicron^a sub-lineages among passengers testing positive for SARS-CoV-2, according to the Chinese town of provenance of their flights to Italy, 26–29 December 2022 (n=55 sequences)^a



SARS-CoV-2: severe acute respiratory coronavirus 2.


^a Omicron (Phylogenetic Assignment of Named Global Outbreak (Pango) lineage B.1.1.529).

^b Of 61 passengers testing positive for SARS-CoV-2 and for whom samples were sequenced, six could not be assigned a sub-lineage due to low sequence coverage.

The disks (pie charts) are subdivided according to the proportion of each sub-lineage found. The numbers at the centres of the disks represent the total number of characterised viral sequences that were obtained through the travellers to Italy from the Chinese geographical locations in question.

FIGURE 2

Geographic distribution by province of Omicron^a sub-lineages among sequences^b with case date after 1 September 2022 deposited from China in GISAID as of 11 January 2023 (n = 627 sequences)



^a Omicron (Phylogenetic Assignment of Named Global Outbreak (Pango) lineage B.1.1.529).

^b In the respective metadata, the deposited sequences were not labelled in as 'imported'.

Other lineages include BA.5.2 (n=9), BF.21 (n=3), BF.7 (n=1), BA.5.1 (n=8) in Beijing, BA.2 (n=4), BA.5 (n=1), BA.5.1 (n=1), BA.5.2.1 (n=4), other BA.5.2.* (n=34), BE.1.4.2 (n=1), BF.7 (n=3), BQ.1 (n=1), BQ.1.1 (n=4), BQ.1.1.4 (n=1), BQ.1.23 (n=1), CH.1.1 (n=1) in Shanghai, BA.5.2 in Gansu (n=2), BA.5.2 in Hunan (n=2), BA.5 (n=1) and BA.5.2 (n=1) in Guangdong, and BA.5.1 (n=1) in Sichuan.

The disks (pie charts) are subdivided according to the proportion of each sub-lineage found. The numbers at the centres of the disks represent the total number of characterised viral sequences that originated from the provinces in question.

On 11 January 2023 Chinese scientists deposited 708 SARS-CoV-2 sequences from China in GISAID. These were from samples from 19 November to 5 January 2023, which were not labelled as ‘imported’ in metadata.

They come from 10 Chinese towns, and the distribution of sub-lineages is depicted according to the province or region that the towns belong to in Figure 2; sequences in our cohort largely overlap in type and frequency of detected sub-lineages with the GISAID sample, thereby aligning with Chinese-released data; however, data are still lacking from some parts of central and western China. While there is no reason at the moment to be concerned about novel variants [7], ongoing monitoring is strongly recommended for such an unprecedented situation.

Discussion

In this study, we tested 556 flight passengers in provenance from China for SARS-CoV-2. Whole genome sequencing of samples respectively obtained from 61 passengers who tested positive for the virus revealed Omicron variants, notably sub-lineages BA.5.2, BF.7, and BQ.1.1 (each with additional mutations), in line with data released from China.

Among those dominant sub-lineages, BF.7.14 (i.e. BF.7+ORF7a:H47Y+S:C1243F) deserves a special attention: BF.7, which is characterised by the S:R346T immune escape mutation, is resistant to cilgavimab+tixagevimab but instead retains sensitivity to bebtelovimab [8-10] and convalescent plasma from vaccinees [11]. So far COVID-19 waves have been driven by SARS-CoV-2 variant of concerns (VOC) associated with major changes in the RBD of the spike protein, but mutations in the S2 subunit of spike such as C1243F are unlikely to drive immune evasion. Hence, attention should be paid at the role of ORF7a:H47Y. ORF7a is an accessory cysteine-rich, zinc-binding type I transmembrane protein structurally conserved throughout the different SARS-CoV-2 VOC. It includes three separate domains: an N-terminal signal sequence (15 residues), an ectodomain with Ig-like fold (beta sandwich), a short transmembrane domain, and a C-terminal cytoplasmic tail containing a di-lysine motif (¹¹⁷KRKTE¹²¹) for endoplasmic reticulum (ER) localisation. Among the various interactions with host proteins, ORF7a interacts specifically with the major histocompatibility complex (MHC)-I heavy chain, acting as a molecular mimic of β_2 -microglobulin (β_2m) to inhibit MHC-I heavy chain association with β_2m ; this slows the exit of properly assembled MHC-I molecules from the ER [12], potentially limiting cell-mediated immune responses. Zheng et al. found that F59, absent in SARS-CoV, is associated with such function [13]. ORF7a genetic sequence is also the origin for CoV2-miR-O7a, a viral miRNA-like small RNA which modulates interferon signalling via basic leucine zipper ATF-Like transcription factor 2 (BATF2) [14]. ORF7a:H47Y mutation in the ectodomain had been previously reported from Oceania and North America as early as in 2020 [15], and in the BF.5 lineage which

is dominant in Japan at the end of 2022. Several other mutations, also around the F59 position, emerged recently (e.g. S44P in BA.5.11 and T61S in XAY) [16,17]. Several gain-of-function ORF7a mutations have already been associated with more severe disease presentations, e.g. A105V [18].

Inactivated whole-virus vaccines (CoronaVac from Sinovac Biotech Ltd and BBIBP-CorV from Sinopharm, Beijing, China) have been largely deployed in China, with a mean of 2.1 doses per inhabitant [19]. However, less than half of people aged 80 years and over have received three doses of the vaccine [20]. Those vaccines achieve lower risk reduction for hospitalisation [21], and lower neutralising antibodies geometric mean titres than spike-only mRNA vaccines [22]. The latter outcome could reduce the selective pressure for SARS-CoV-2 to evade anti-spike antibody response, maintaining however pressure on viral selective mechanisms to escape host cell-mediated immune response.

The BF.7 variant has been circulating in United States and Europe since August 2022 [12-14], and in Inner Mongolia since September 2022. The apparently high prevalence of BF.7.14 in China is presumably due to a founder effect: selection pressure from immune escape is much lower in China, where the contribution of previous infection-elicited immunity is less relevant than elsewhere, so it makes sense not to expect a rapid takeover by BQ.1* and XBB*. With 5 million new cases per day estimated in China, the evolution of the situation is somewhat uncertain [23].

Limitations of this study include the small sample size, the biased clinical presentation (only asymptomatic or mild patients are likely to embark on intercontinental flights and pass security checks) and the geographic restriction to the East of China.

Conclusion

Our findings agree with sequencing data released from China and underline the relevance of genomic surveillance to detect evolution of dominant lineages in a large ecological setting. Such setting, consisting mostly of a highly vaccinated but infection-naïve population is so far unprecedented in the COVID-19 pandemic.

Ethical statement

The work was performed as part of emergency surveillance activities in Italy, in accordance with the ordinance of December 28, 2022, by Ministry of Health: “Misura urgente in materia di contenimento e gestione dell’epidemia da COVID-19 concernenti gli ingressi dalla Cina”.

Funding statement

This research was supported by the Italian Ministry of Health, Ricerca Corrente INMI Spallanzani - Line 1.

Data availability statement

The sequences generated and analysed during the current study are available in the GISAID repository.

Acknowledgements

We gratefully acknowledge Federico Gueli for his valuable feedback and discussions on SARS-CoV-2 genomic epidemiology. We gratefully acknowledge the authors, the originating and submitting laboratories for their sequence and metadata shared through GISAID (<https://gisaid.org/>).

Conflict of interest

None declared.

Authors' contributions

FN, DF, FM initially conceived the work. MR, AB, LF, AG, FDF, SB, GG, CM, OB, RP performed the sample preparation and sequencing analysis. EG, AG, CEMG, DF performed the interpretation of the sequence data. FN, DF, FM drafted the manuscript. AC, AA, EG, FV critically revised the manuscript. All authors approved the final version to be published.

References

- Owens D, Parry J. Covid-19: What can China learn from Hong Kong and Singapore about exiting zero covid? *BMJ*. 2022;379:03043. <https://doi.org/10.1136/bmj.03043> PMID: 36543337
- European Centre for Disease Prevention and Control (ECDC). Impact of surge in China COVID-19 cases on epidemiological situation in EU/EEA. Stockholm: ECDC; 3 Jan 2023. Available from: <https://www.ecdc.europa.eu/en/news-events/impact-surge-china-covid-19-cases>
- Leung K, Lau EHY, Wong CKH, Leung GM, Wu JT. Estimating the transmission dynamics of Omicron in Beijing, November to December 2022. *medRxiv*. 2022; 12.28.
- Centers for Disease Control and Prevention (CDC). CDC Announces Negative COVID-19 Test Requirement from Air Passengers Entering the United States from the People's Republic of China. Atlanta: CDC; 28 Dec 2022. Available from: <https://www.cdc.gov/media/releases/2022/p1228-COVID-china.html>
- Covid in China. US imposes Covid testing for visitors from China; 29 Dec 2022. [Accessed: 19 Dec 2022]. Available from: <https://www.bbc.com/news/world-asia-china-64111492>
- Ministerio della Salute. COVID-19, travellers. The measures for entry into Italy. [Accessed 10 Jan 2023]. Available from: <https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?lingua=english&id=5412&area=nuovoCoronavirus&menu=vuoto>
- World Health Organization (WHO). TAG-VE statement on the meeting of 3 January on the COVID-19 situation in China. Geneva: WHO; 4 Jan 2023. Available from: <https://www.who.int/news/item/04-01-2023-tag-ve-statement-on-the-3rd-january-meeting-on-the-covid-19-situation-in-china>
- Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. *Nature*. 2022;19:12. <https://doi.org/10.1038/s41586-022-05644-7> PMID: 36535326
- Jian F, Yu Y, Song W, Yisimayi A, Yu L, Gao Y, et al. Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants. *Lancet Infect Dis*. 2022;22(11):1535-7. [https://doi.org/10.1016/S1473-3099\(22\)00642-9](https://doi.org/10.1016/S1473-3099(22)00642-9) PMID: 36179744
- Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Mohri H, et al. Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation. *Lancet Infect Dis*. 2022;22(12):1666-8. [https://doi.org/10.1016/S1473-3099\(22\)00694-6](https://doi.org/10.1016/S1473-3099(22)00694-6) PMID: 36328002
- Sullivan DJ, Franchini M, Senefeld JW, Joyner MJ, Casadevall A, Focosi D. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potentially neutralizes BQ1.1 and XBB. *bioRxiv*. 2022; 11.25.
- Arshad N, Laurent-Rolle M, Ahmed WS, Hsu JCC, Mitchell SM, Pawlak J, et al. SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression. *Proc Natl Acad Sci U S A*. 2023;120(1):e2208525120. <https://doi.org/10.1073/pnas.2208525120> PMID: 36574644
- Zheng S, de Buhr H, Praest P, Evers A, Brak-Boer I, van Grinsven M, et al. The SARS-CoV-2 accessory factor ORF7a downregulates MHC class I surface expression. *bioRxiv*. 2022; 05.29. <https://doi.org/10.1101/2022.05.29.493850>
- Pawlica P, Yario TA, White S, Wang J, Moss WN, Hui P, et al. SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes. *Proc Natl Acad Sci U S A*. 2021;118(52):e2116668118. <https://doi.org/10.1073/pnas.2116668118> PMID: 34903581
- Hassan SS, Choudhury PP, Dayhoff GW 2nd, Aljabali AAA, Uhal BD, Lundstrom K, et al. The importance of accessory protein variants in the pathogenicity of SARS-CoV-2. *Arch Biochem Biophys*. 2022;717:109124. <https://doi.org/10.1016/j.abb.2022.109124> PMID: 35085577
- covSPECTRUM. ORF7a:S44P search from 2022-07-11 to 2023-01-04. Available from: <https://cov-spectrum.org/explore/World/AllSamples/Past6M/variants?aaMutations=ORF7a%3AS44P&>
- covSPECTRUM. ORF7a:T61S search from 2022-07-11 to 2023-01-04. Available from: <https://cov-spectrum.org/explore/World/AllSamples/Past6M/variants?aaMutations=ORF7a%3AT61S&>
- Lobiuc A, Șterbuleac D, Sturduza O, Dimian M, Covasa M. A conservative replacement in the transmembrane domain of SARS-CoV-2 ORF7a as a putative risk factor in COVID-19. *Biology (Basel)*. 2021;10(12):1276. <https://doi.org/10.3390/biology10121276> PMID: 34943191
- Mainland China. the latest coronavirus counts, charts and maps. [Accessed: 29 Dec 2022]. Available from: <https://www.reuters.com/graphics/world-coronavirus-tracker-and-maps/countries-and-territories/china>
- China Covid: What is China's policy and how many cases are there? BBC: Reality check. [Accessed: 20 Dec 2022]. Available from: <https://www.bbc.com/news/59882774>.
- Tan CY, Chiew CJ, Lee VJ, Ong B, Lye DC, Tan KB. Comparative effectiveness of 3 or 4 doses of mRNA and inactivated whole-virus vaccines against COVID-19 infection, hospitalization and severe outcomes among elderly in Singapore. *Lancet Reg Health West Pac*. 2022;29:100654. <https://doi.org/10.1016/j.lanwpc.2022.100654> PMID: 36471699
- Premikha M, Chiew CJ, Wei WE, Leo YS, Ong B, Lye DC, et al. Comparative effectiveness of mRNA and inactivated whole-virus vaccines against coronavirus disease 2019 infection and severe disease in Singapore. *Clin Infect Dis*. 2022;75(8):1442-5. <https://doi.org/10.1093/cid/ciac288> PMID: 35412612
- COVID-19 projections in China by Institute for Health Metrics and Evaluation at the University of Washington, Seattle. [Accessed: 4 Jan 2023]. Available from: <https://covid19.healthdata.org/china?view=mask-use&tab=trend>

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2023.